www.3sbio.com 提示:

本信息仅供医学专业人士参考,如果您是医学专业人士,请点击确定后进入。 如果不是,请点击取消。

取消 确定

Products and services

In 3SBio, meeting the needs of patients is the core of all actions.

Our global list of drug combinations

The following is a list of products listed by our company, which is only for medical professionals to refer to.

TPIAO (Recombinant human thrombopoietin (rhTPO))

In 2005, TPIAO was listed and has been approved by the CFDA for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (ITP) (approved in 2010), which is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

Indication Manufacturing base Dosage form & Dosage

Treatment for chemotherapy-induced thrombocytopenia (CIT);
Treatment for immune thrombocytopenia (ITP).

Shenyang manufacturing base

7500 U/1 ml; 15000 U/1 ml

Ruisiyi (Anastrozole)

Ruisiyi is a potent non-steroidal aromatase inhibitor and is suitable for advanced breast cancer that is not controlled by tamoxifen and other anti-estrogen therapies in postmenopausal women. Ruisiyi is the first line drug for breast cancer, showing good tolerance, and it can effectively increase patients’survival. It is included in the National Medical Insurance Catalogue as a Category B drug.

Indication Manufacturing base Dosage form & Dosage
Treatment for advanced breast cancer in postmenopausal women;
Treatment for early-stage breast cancer in postmenopausal women with positive hormone receptor.
Zhejiang manufacturing base 12.5 mg/bottle; 25 mg/bottle

Wanwei (Azasetron Hydrochloride)

Wanwei is a 5-HT3 receptor antagonist antiemetic drug used for vomiting caused by cytotoxic chemotherapy. Wanwei is the first listed generic product among the products of the same type after the original product was approved for import and marketed in China. Compared with other traditional medicines, Wanwei is highly efficient and selective, and can more effectively control delayed vomiting.

Indication Manufacturing base Dosage form & Dosage
Treatment for vomiting caused by cytotoxic chemotherapy; Zhejiang manufacturing base /

Intefen (Recombinant human interferon (α-2a))

In April 1995, Intefen was approved to be manufactured by CFDA.In December 1995, Intefen was launched and is included in the National Medical Insurance Catalogue as a Category B drug.

Indication Manufacturing base Dosage form & Dosage
Treatment of lymphatic or hematopoietic malignancies and viral infections: adult chronic hepatitis B, acute and chronic hepatitis C and condyloma acuminata. Shenyang manufacturing base Injection - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml;
Freeze-dried powder - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml.

Inleusin (Recombinant human interleukin2 (IL-2))

In June 1995, CFDA production approval documents were obtained for Inleusin. This product was launched in March 1996 and is included in the National Medical Insurance Catalogue as a Category B drug.

Indication Manufacturing base Dosage form & Dosage
Treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis. Shenyang manufacturing base 100,000 IU/bottle; 200,000 IU/bottle; 500,000 IU/bottle; 1,000,000 IU/bottle